To report the FDA approval of NEREUS (tradipitant) for the prevention of motion-induced vomiting in adults.
Approach:
Key Findings:
In Motion Syros (n = 365), vomiting occurred in 18% to 20% of patients receiving tradipitant versus 44% receiving placebo.
In Motion Serifos (n = 316), vomiting rates ranged from 10% to 18% with tradipitant versus 38% with placebo.
Risk reductions of 50% to 70% were observed across studies.
Tradipitant showed a favorable safety profile with common adverse reactions including somnolence and fatigue.
Interpretation:
The approval of tradipitant marks a significant advancement in the treatment of motion sickness, providing a new option for patients who have limited success with existing therapies.
Limitations:
Safety and effectiveness have not been established in pediatric patients.
Use is cautioned in patients with severe renal or hepatic impairment.
Conclusion:
Tradipitant offers a novel therapeutic approach to motion sickness, leveraging modern neuropharmacology to improve patient outcomes.
Burnout is easing. Sleep science is getting weird. And dental schools have been winging cadaver training for 50 years. This week's research is full of good news that immediately complicates itself.
